KLRA vs WW
KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential. WW: A global weight management and wellness company transitioning its legacy subscription-based coaching and nutrition programs to a digital-first platform in an era of weight-loss pharmaceuticals.
Side-by-side fundamentals
| Metric | KLRA | WW | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $17.48 | $13.85 | |
| Market cap as of 2026-07-31 | $2.3B | $127M | |
| P/E as of 2026-07-31 | n/a | 0.12 | |
| Net margin as of 2026-07-31 | n/a | +155.5% | |
| Gross margin as of 2026-07-31 | n/a | +72.0% | |
| Operating margin as of 2026-07-31 | n/a | +166.5% | |
| ROE as of 2026-07-31 | -23.4% | +334.4% | WW higher |
| ROA as of 2026-07-31 | -21.5% | +112.5% | WW higher |
| Debt / equity as of 2026-07-31 | 0.00 | 1.75 | KLRA lower |
| Revenue growth (YoY) as of 2026-07-31 | n/a | -9.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -17.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-31 | 1.71 | 1.20 | |
| 1-year return as of 2026-07-27 close | n/a | -66.2% |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.